We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+7.16%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$7.42B
AUM Growth
+$1.24B
(+20%)
Cap. Flow
+$985M
Cap. Flow
% of AUM
13.27%
Top 10 Holdings %
Top 10 Hldgs %
10.68%
Holding
3,037
New
854
Increased
791
Reduced
777
Closed
600
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$49.3M |
| 2 |
Intuit
INTU
|
+$48.7M |
| 3 |
Costco
COST
|
+$47.9M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$47.4M |
| 5 |
Vanguard Real Estate ETF
VNQ
|
+$45.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$41M |
| 2 |
Dollar General
DG
|
+$39M |
| 3 |
Biogen
BIIB
|
+$36.8M |
| 4 |
iShares US Real Estate ETF
IYR
|
+$29.8M |
| 5 |
Waste Management
WM
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.19% |
| 2 | Consumer Discretionary | 16.12% |
| 3 | Healthcare | 11.21% |
| 4 | Financials | 10.17% |
| 5 | Industrials | 9.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RLH
2351
DELISTED
Red Lions Hotel Corporation
RLH
| $60K | ﹤0.01% |
+28,022
| New | +$64.7K |
|
|
GNCA
2352
DELISTED
Genocea Biosciences, Inc.
GNCA
| $59K | ﹤0.01% |
25,966
-106,582
| -80% | -$280K |
|
2353
Avalo Therapeutics
AVTX
$976M
| $58K | ﹤0.01% |
9
-3
| -25% | -$22.5K |
|
|
FLNT
2354
Fluent
FLNT
$102M
| $58K | ﹤0.01% |
+3,923
| New | +$56.9K |
|
2355
vTv Therapeutics
VTVT
$121M
| $58K | ﹤0.01% |
823
-668
| -45% | -$58.7K |
|
2356
Boxlight
BOXL
$2.37M
| $57K | ﹤0.01% |
+25
| New | +$68.3K |
|
2357
FuelCell Energy
FCEL
$1.7B
| $57K | ﹤0.01% |
+895
| New | +$71.3K |
|
2358
INNOVATE Corp
VATE
$114M
| $57K | ﹤0.01% |
+2,357
| New | +$63.6K |
|
|
EEX
2359
DELISTED
Emerald Holding
EEX
| $56K | ﹤0.01% |
+27,461
| New | +$72.7K |
|
|
DSKE
2360
DELISTED
Daseke, Inc. Common Stock
DSKE
| $56K | ﹤0.01% |
10,450
-18,470
| -64% | -$94.9K |
|
|
NH
2361
DELISTED
NantHealth, Inc
NH
| $56K | ﹤0.01% |
1,604
+857
| +115% | +$48.3K |
|
2362
Safe Bulkers
SB
$781M
| $55K | ﹤0.01% |
53,436
+38,246
| +252% | +$44.3K |
|
2363
Genprex
GNPX
$3.94M
| – | – |
0
| – | – |
|
2364
PAVmed
PAVM
$33.9M
| $52K | ﹤0.01% |
65
+42
| +183% | +$37.4K |
|
|
LJPC
2365
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $52K | ﹤0.01% |
+12,998
| New | +$53.8K |
|
|
ACR
2366
ACRES Commercial Realty
ACR
$126M
| $51K | ﹤0.01% |
8,187
-7,541
| -48% | -$52.3K |
|
|
CLSD
2367
DELISTED
Clearside Biomedical
CLSD
| $51K | ﹤0.01% |
+2,189
| New | +$56.6K |
|
2368
Marchex
MCHX
$79.7M
| $51K | ﹤0.01% |
+24,254
| New | +$42.7K |
|
2369
Ramaco Resources Class A
METC
$676M
| $51K | ﹤0.01% |
+15,096
| New | +$39K |
|
|
ANH
2370
DELISTED
Anworth Mortgage Asset Corporation
ANH
| $51K | ﹤0.01% |
31,081
-194,571
| -86% | -$341K |
|
2371
Clean Energy Fuels
CLNE
$447M
| $50K | ﹤0.01% |
+20,161
| New | +$52.5K |
|
|
APHA
2372
DELISTED
Aphria Inc. Common Shares
APHA
| $50K | ﹤0.01% |
+11,301
| New | +$52.8K |
|
2373
United Microelectronic
UMC
$48.9B
| $49K | ﹤0.01% |
+10,270
| New | +$38.1K |
|
|
HEPA
2374
DELISTED
Hepion Pharmaceuticals
HEPA
| $48K | ﹤0.01% |
16
+3
| +23% | +$10.8K |
|
2375
Arq
ARQ
$86.9M
| $48K | ﹤0.01% |
11,778
-13,354
| -53% | -$57.1K |
|
Similar funds
Squarepoint's Q3 2020 Portfolio in Review
As of Q3 2020, Squarepoint held 3,037 positions worth $7.42B, up 20% from $6.18B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Squarepoint deployed $985M of net new capital in Q3 2020, opening 854 new positions and adding to 791 existing holdings. Its largest new stake was Salesforce: 186,017 shares worth $46.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Pfizer, an estimated $41M trimmed.
- Squarepoint's largest Q3 2020 buy was Salesforce: 186,017 shares worth $46.8M.
- Squarepoint added most to Visa in Q3 2020, an estimated $49.3M increase.
- Squarepoint's biggest Q3 2020 reduction was Pfizer, cutting an estimated $41M.
- Squarepoint fully exited Biogen in Q3 2020, selling an estimated $36.8M.
- Squarepoint's ten largest holdings make up 11% of its $7.42B portfolio in Q3 2020.
- Squarepoint opened 854 new positions and closed 600 in Q3 2020.
- Squarepoint's portfolio value rose 20% quarter-over-quarter to $7.42B.
Based on Squarepoint's 13F filing for Q3 2020, filed 16 Nov 2020.